Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study | Zendy

Michael Gold | Zendy; Claire Alderton | Zendy; Marina ZvartauHind | Zendy; Sally Egginton | Zendy; Ann M. Saunders | Zendy; Michael C. Irizarry | Zendy; Suzanne Craft | Zendy; Gary E. Landreth | Zendy; Ülla Linnamägi | Zendy; Sharon Sawchak | Zendy

Open Access

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Author(s) -

Michael Gold,

Claire Alderton,

Marina ZvartauHind,

Sally Egginton,

Ann M. Saunders,

Michael C. Irizarry,

Suzanne Craft,

Gary E. Landreth,

Ülla Linnamägi,

Sharon Sawchak

Publication year - 2010

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000318845

Subject(s) - placebo , medicine , tolerability , donepezil , alzheimer's disease , randomized controlled trial , apolipoprotein e , psychology , adverse effect , gastroenterology , dementia , disease , pathology , alternative medicine

A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research